Drug Profile
GOVX B21
Alternative Names: DNA G/MVA adjuvanted vaccine; DNA-G/MVA; GM CSF adjuvanted pGA2/JS7 + MVA/HIV62Latest Information Update: 19 Feb 2024
Price :
$50
*
At a glance
- Originator GeoVax Labs; National Institutes of Health (USA)
- Developer GeoVax Labs
- Class AIDS vaccines; DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued HIV-1 infections
Most Recent Events
- 13 Feb 2024 GeoVax Labs receives patent protection for Multivalent HIV Vaccine Boost Compositions and Methods of Use
- 05 Oct 2023 GeoVax Labs receives a Notice of Allowance for Multivalent HIV Vaccine Boost Compositions and Methods of Use
- 20 Oct 2016 Immunogenicity data from a phase I trial in HIV-1 infections released by GeoVax